anti-cd19/cd20/cd22 car t-cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2022 (NCT05418088)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Prolymphocytic, B-Cell · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
- CD22Immunity, passive
CD22 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07168486 | Phase 1 | Oct 28, 2024 | University of Maryland |
| NCT05418088 | Phase 1 | Jun 30, 2022 | Ohio State University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ohio State University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Maryland | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1